Summary

Gulf oysters and FATE get a shoutout in this episode of Melanoma Matters. Hosts James Larkin and Sapna Patel discuss the ADAPT-IT study, focusing on adaptive dosing strategies in immunotherapy for melanoma. They explore the study's design, results, and implications for clinical practice, including the potential for reduced dosing based on early response assessments.

Keywords

ADAPT-IT study, immunotherapy, melanoma, adaptive dosing, clinical efficacy, treatment response, toxicity management, cancer research

Takeaways

The ADAPT-IT study explores adaptive dosing in immunotherapy.

68% of patients showed favorable anti-tumor effects after two doses.

Early response assessments can guide treatment decisions.

The study suggests that two doses may be sufficient for some patients.

There is potential for one dose to be effective in certain cases.

Reimbursement policies may influence treatment strategies.

Correlative studies provide insights into treatment efficacy.

Management of toxicity is crucial in immunotherapy.

The conversation highlights the importance of clinical intuition.

Future research may refine dosing strategies further.

Sound Bites

"Is two cycles enough?"

"68% had a favorable anti-tumor effect."

"Could one dose be enough?"

Chapters

00:00 Introduction to the ADAPT-IT Study

04:12 FATE v non-FATE

06:03 Clinical Implications of Early Response Assessment

09:02 Results and Efficacy of the Study

11:50 Discussion

14:18 Exploring the Role of LDH in Treatment Decisions

17:32 Correlative Studies and Future Directions

20:14 Toxicity and Management Strategies

22:58 Correlatives (ctDNA)

30:54 Bit of good news about NADINA